Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) - Aug 14, 2023 - "During the remainder of 2023, the Company plans to accomplish the following key business objectives: (i) Initiate Phase 1/Part B of the ReSPECT-LM trial; (ii) Obtain FDA approval and initiate the Phase 1 ReSPECT-PBC trial for pediatric patients with ependymoma and high-grade glioma at Lurie Children’s Hospital in Chicago; (iii) Publish ReSPECT-GBM Phase 1 data in peer-reviewed publication; (iv) Present safety and efficacy data from ReSPECT-GBM trials at the annual SNO conference in Vancouver on November 16-19, 2023."
New P1 trial • P1 data • Trial status • Brain Cancer • CNS Tumor • Ependymoma • Glioblastoma • Glioma • Oncology • Solid Tumor
|